# VISION (NCT03511664)

> Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: lutetium lu 177 vipivotide tetraxetan (177Lu-PSMA-617)
- Indication: PSMA-positive metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03511664
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Endocyte
- Conditions: Prostate Cancer
- Interventions: 177Lu-PSMA-617; Best supportive/best standard of care
- Enrollment: 861
- Primary outcome: Radiographic Progression-free Survival (rPFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on VISION so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=vision-nct03511664